These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16676183)

  • 21. Dendritic cell-based vaccines in patients with hematological malignancies.
    Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
    Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.
    Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H
    Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
    Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
    J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
    Li A; Xiong S; Lin Y; Liu R; Chu Y
    DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].
    He B; Qiu G; Xie X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):974-8. PubMed ID: 15646345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program.
    Cochlovius B; Stassar M; Christ O; Raddrizzani L; Hammer J; Mytilineos I; Zöller M
    J Immunol; 2000 Oct; 165(8):4731-41. PubMed ID: 11035118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
    Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
    Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.
    Schuler-Thurner B; Dieckmann D; Keikavoussi P; Bender A; Maczek C; Jonuleit H; Röder C; Haendle I; Leisgang W; Dunbar R; Cerundolo V; von Den Driesch P; Knop J; Bröcker EB; Enk A; Kämpgen E; Schuler G
    J Immunol; 2000 Sep; 165(6):3492-6. PubMed ID: 10975870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.
    Colombo BM; Lacave R; Pioche-Durieu C; Masurier C; Lemoine FM; Guigon M; Klatzmann D
    Immunology; 2000 Jan; 99(1):8-15. PubMed ID: 10651935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
    Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
    Front Immunol; 2020; 11():602802. PubMed ID: 33281829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC.
    Nourizadeh M; Masoumi F; Memarian A; Alimoghaddam K; Moazzeni SM; Yaghmaie M; Hadjati J
    Target Oncol; 2014 Sep; 9(3):225-37. PubMed ID: 23852664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.